Vicarious Surgical's future product and service offerings, and its ability to serve those markets once commercialized, either alone or in partnership with others; Vicarious Surgical's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; Vicarious Surgical's ability to raise financing in the future; Vicarious Surgical's financial performance; Vicarious Surgical's intellectual property rights and how failure to protect or enforce these rights could harm its bu ...

Financial Performance - Vicarious Surgical reported an adjusted net loss of $15.3 million for Q1 2025, equating to an adjusted loss per share of $2.58, compared to an adjusted net loss of $15.1 million and a loss per share of $2.58 in Q1 2024[6]. - The GAAP net loss for Q1 2025 was $15.4 million, or $2.60 per share, compared to a GAAP net loss of $17.0 million, or $2.90 per share, in Q1 2024[6]. - The company had a comprehensive net loss of $15.4 million for Q1 2025, compared to a comprehensive net loss of $17.1 million in Q1 2024[16]. Operating Expenses - The company's total operating expenses for Q1 2025 were $15.7 million, a decrease of 2% from $16.1 million in the same period last year[6]. - Research and development expenses for Q1 2025 were $9.4 million, down from $10.0 million in Q1 2024[6]. Cash Position - Cash and investments as of March 31, 2025, totaled $37.4 million, with a cash burn rate of $11.7 million for the first quarter[6]. - Vicarious Surgical expects a full-year cash burn of approximately $50 million for 2025[5]. Assets and Deficit - Total assets decreased from $67.7 million as of December 31, 2024, to $55.1 million as of March 31, 2025[18]. - Vicarious Surgical's accumulated deficit increased to $211.3 million as of March 31, 2025, from $195.9 million at the end of 2024[18]. Clinical Milestones - The company is on track to achieve its first clinical patients within the next few quarters, marking a significant milestone in its transition to a clinical-stage company[3].

Vicarious Surgical (RBOT) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Webb Campbell - Vice PresidentAdam Sachs - Co-Founder & CEOSarah Romano - CFOEric Anderson - Vice President Equity Research Conference Call Participants None - Analyst Operator Hello, everyone, and welcome to the Vicarius Surgical twenty twenty five First Quarter Earnings Call. My name is Nadia, and I'll be coordinating the call today. Will now hand over to your host, Webb Campbell, Investor Relations, to begin. We ...

Vicarious Surgical (RBOT) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Speaker0 Hello, everyone, and welcome to the Vicarius Surgical twenty twenty five First Quarter Earnings Call. My name is Nadia, and I'll be coordinating the call today. Will now hand over to your host, Webb Campbell, Investor Relations, to begin. Webb, please go ahead. Speaker1 Good afternoon. Today, after market close, Vicarious Surgical released financial results for the three months ended 03/31/2025. A copy of the press release is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39384 VICARIOUS SURGICAL INC. (Exact name of registrant as specified in its charter) Delaware 87-2678169 (State or other jurisd ...

Core Viewpoint - Vicarious Surgical Inc. (RBOT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the correlation between changes in earnings estimates and stock price movements, driven by institutional investors who adjust their valuations based on these estimates [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional buying or selling, which in turn affects stock prices [4]. Company-Specific Insights - For Vicarious Surgical, the upgrade reflects an improvement in the company's underlying business, suggesting that investor sentiment will likely drive the stock price higher [5]. - The Zacks Consensus Estimate for the company has increased by 15.9% over the past three months, with an expected earnings per share of -$7.15 for the fiscal year ending December 2025, representing a year-over-year change of 33.5% [8]. Zacks Rating System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 positions Vicarious Surgical in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Financial Data and Key Metrics Changes - Total operating expenses for full year 2024 were $66.6 million, down 17% year-over-year [24] - R&D expenses for the full year 2024 were $40.2 million, down from $47.6 million in 2023 [24] - GAAP net loss for full year was $63.2 million, equating to a net loss of $10.74 per share, compared to a GAAP net loss of $71.1 million or $14.60 per share for the full year 2023 [25] Business Line Data and Key Metrics Changes - General and administrative expenses totaled $21.9 million in the full year 2024, down from $26.9 million in 2023 [24] - Sales and marketing expenses were $4.5 million compared to $6.2 million in the prior year [24] Market Data and Key Metrics Changes - The company has expanded its partnerships with leading U.S. hospital systems, including LSU Health New Orleans, Temple Health, and University of Illinois Health [13][15] - The company is preparing for its first clinical use of the Version 1.0% system, which is expected to treat patients later in the year [21] Company Strategy and Development Direction - The company aims to transition into a clinical stage company in 2025, with a focus on robotic surgery innovations [8] - The Version 1.0% system is designed to deliver differentiated value to patients, surgeons, and hospitals, with a focus on minimally invasive outcomes [10][12] - The company is building a robust supply chain and manufacturing foundation to support its clinical trials and future growth [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed excitement about the successful completion of the Version 1.0% system integration and the potential impact on surgical procedures [9][28] - The company anticipates treating its first clinical patients by year-end 2025, with a de novo submission expected to be late in 2026 [21][26] Other Important Information - The company has faced some procurement challenges with key suppliers, but has managed to mitigate the impact on its timelines [20][36] - A new CFO, Sarah Romano, will join the company on April 1, bringing extensive financial leadership experience [22][23] Q&A Session Summary Question: Can you provide details on the supplier dynamic and its impact on clinical trial manufacturing? - Management acknowledged material procurement challenges with key suppliers that led to delays in component deliverables, but noted that they have resumed production [35][37] Question: When do you anticipate the clinical trial beginning? - Management indicated that the first patients will be treated later in the year, with plans to kick off pivotal trials shortly after [41][42] Question: Can you provide timing around the dossier submission? - The dossier submission is expected around the middle of the year, with the first patient timing dependent on approval [51] Question: What were the results of the cadaver lab tests? - The cadaver labs successfully performed ventral hernia repairs, and management expressed confidence in the system's performance [61] Question: Any updates on clinical trial design and patient expectations? - Management confirmed that trial design will be finalized after the first patients, allowing for flexibility in protocol adjustments [64]

Vicarious Surgical Inc. (NYSE:RBOT) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Kaitlyn Brosco - Director-IR Adam Sachs - Co-Founder and CEO Randy Clark - President Conference Call Participants Ryan Zimmerman - BTIG Adam Maeder - Piper Sandler Josh Jennings - Cowen Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2024 Fourth Quarter and Full Year Earnings Call. My name is Cameron and I will be your moderator for today. All lines have been muted du ...

Financial Performance and Position - The company has incurred an accumulated deficit of $195.9 million as of December 31, 2024, with net losses of $63.2 million and $71.1 million for the years ended December 31, 2024 and 2023, respectively[128][129]. - As of December 31, 2024, the company held cash and cash equivalents of $9.7 million and short-term investments of $39.4 million, which are expected to fund operations only into the first quarter of 2026[128][132]. - The company has not generated any revenue from the sales of the Vicarious Surgical System to date and anticipates continuing to incur significant losses for several years as it develops and commercializes the system[129][131]. - Future revenue generation is heavily dependent on the successful commercialization of the Vicarious Surgical System and the establishment of a sales and distribution network[131][139]. - The company recorded a full valuation allowance related to its NOLs and other deferred tax assets due to uncertainty regarding the realization of future benefits[187]. - As of December 31, 2024, the company had federal net operating loss carry forwards (NOLs) of approximately $165.1 million, with about $2.8 million set to expire between 2034 and 2037 if not utilized[187]. Market and Competitive Landscape - The company faces substantial competition from established companies in the robotic-assisted surgical market, including Intuitive Surgical, Johnson & Johnson, and Medtronic, which may impact its ability to generate future revenue[138][137]. - The company aims to commercialize the Vicarious Surgical System initially for ventral hernia repair procedures, with plans to expand into gynecological, urological, and other general surgical applications[135][139]. - Competition in the medical device industry is intense, with major competitors like Intuitive Surgical and Johnson & Johnson having greater resources, which could impact the company's market position[148]. - The introduction of new products by competitors could render the company's offerings obsolete, affecting future revenue and market acceptance[176]. Regulatory and Compliance Challenges - The company must navigate regulatory challenges and maintain compliance to successfully launch the Vicarious Surgical System in the market[140][135]. - The company is subject to extensive government regulation, which could restrict the development and marketing of its product candidates, potentially leading to significant costs[193]. - The FDA's review process for premarket notifications typically takes 90 to 180 days, while De Novo classification applications can take 120 to 280 days, with potential for longer delays[196]. - There is no guarantee that the FDA will grant marketing authorization for the Vicarious Surgical System or any future product candidates, which could hinder business growth[204]. - Compliance with regulatory requirements includes post-market surveillance and inspections, which may involve significant operational disruptions[200]. Operational Risks - The company faces challenges in establishing relationships with key surgeons, hospitals, and ASCs due to existing ties with larger medical device companies, which may hinder effective marketing of the Vicarious Surgical System[142]. - Manufacturing delays or problems could limit revenue growth and increase losses, impacting the company's operational results[160]. - The company relies on limited suppliers for key components, and losing these suppliers could necessitate redesigns and significantly affect business operations[163]. - The company faces challenges in developing and optimizing sales and distribution channels, which could negatively impact operating results and customer experience[167]. Intellectual Property and Legal Risks - The company relies on patent protection to maintain a competitive advantage, but uncertainties exist regarding the validity and enforceability of its patents[246]. - Litigation over intellectual property rights could be costly and time-consuming, with unfavorable outcomes potentially impacting the company's business[263]. - The company may face significant expenses and resource consumption when challenging third-party patents through USPTO or EPO proceedings[266]. - Adverse outcomes in intellectual property litigation could lead to diminished perceived value of the company's product candidates and negatively impact stock prices[267]. Management and Personnel - The company is highly dependent on the contributions of its co-founders and key personnel, and losing them could adversely affect business operations[150]. - The company must continue to recruit and retain effective sales and marketing personnel to achieve market awareness and sales success for the Vicarious Surgical System[170]. Financial and Market Risks - Economic downturns could weaken demand for the company's products and hinder capital raising efforts[177]. - Decreasing prices for the Vicarious Surgical System due to market pressures could adversely affect the company's financial condition if expenses are not reduced accordingly[159]. - The company anticipates incurring additional costs to remediate identified control deficiencies, which may not guarantee success[186]. Corporate Governance and Structure - The company is classified as an "emerging growth company" and a "smaller reporting company," allowing it to take advantage of certain exemptions from disclosure requirements, which may affect the attractiveness of its securities to investors[300][302]. - Approximately 71.7% of the voting power is held by Adam Sachs, Sammy Khalifa, and Barry Greene, which may lead the company to become a "controlled company" under NYSE standards[313]. - The board of directors can issue preferred stock without stockholder approval, which could significantly dilute the ownership of a hostile acquirer[306].

Financial Performance - Vicarious Surgical achieved a cash burn of $49.1 million for the full year 2024, in line with guidance of approximately $50 million[7]. - Adjusted net loss for Q4 2024 was $14.4 million, or $2.43 per share, compared to an adjusted net loss of $14.6 million, or $2.50 per share, in Q4 2023[8]. - Net loss for the three months ended December 31, 2024, was $13,926 thousand, compared to a loss of $13,111 thousand in the same period of 2023[23]. - Adjusted net loss for the twelve months ended December 31, 2024, was $63,266 thousand, down from $76,262 thousand in 2023, indicating an improvement of approximately 16.9%[23]. - Adjusted EPS for the three months ended December 31, 2024, was $(2.43), slightly better than $(2.50) in 2023[23]. Expenses - Operating expenses for Q4 2024 were $15.0 million, a decrease of 3% compared to $15.5 million in Q4 2023[5]. - R&D expenses for the full year 2024 were $40.2 million, down from $47.6 million in 2023[6]. - General and administrative expenses for the full year 2024 were $21.9 million, compared to $26.9 million in 2023[6]. - Sales and marketing expenses for the full year 2024 were $4.5 million, down from $6.2 million in 2023[6]. Assets and Liabilities - Total assets decreased from $119,864 thousand in 2023 to $67,719 thousand in 2024, a decline of approximately 43.5%[20]. - Current assets fell from $100,953 thousand in 2023 to $51,698 thousand in 2024, representing a decrease of about 48.9%[20]. - Total liabilities decreased from $21,895 thousand in 2023 to $21,021 thousand in 2024, a reduction of about 4%[20]. - The company reported a total current liabilities increase from $7,280 thousand in 2023 to $7,667 thousand in 2024, an increase of approximately 5.3%[20]. - Stockholders' equity dropped significantly from $97,969 thousand in 2023 to $46,698 thousand in 2024, a decline of approximately 52.4%[20]. Strategic Developments - The company completed the integration of its Version 1.0 system and is preparing for its first clinical patients in 2025[2]. - The company has expanded strategic partnerships with LSU Health New Orleans, Temple Health, and University of Illinois Health[5]. - Vicarious Surgical appointed Sarah Romano as Chief Financial Officer, effective April 1, 2025[5]. Shareholder Information - Weighted average shares outstanding increased from 4,866,880 in 2023 to 5,885,589 in 2024, reflecting a rise of about 20.9%[23]. - The change in fair value of warrant liabilities for the twelve months ended December 31, 2024, was $43 thousand, compared to $5,191 thousand in 2023[23].